What is Precision BioScience?
Headquartered in Durham, North Carolina, Precision BioScience operates at the intersection of advanced genetic engineering and therapeutic development. By leveraging a proprietary genome editing method, the company is uniquely positioned to tackle high-unmet-need medical conditions, including various forms of cancer and hereditary genetic disorders. Beyond human health, the firm is actively exploring applications for its technology to enhance the productivity and safety of global food sources. This dual-focus approach, combined with a robust intellectual property portfolio, establishes Precision BioScience as a critical player in the evolving landscape of synthetic biology and precision medicine.
How much funding has Precision BioScience raised?
Precision BioScience has raised a total of $321M across 4 funding rounds:
Series A
$25.6M
Series B
$110M
Debt
$40M
Stock Offering
$145.4M
Series A (2015): $25.6M with participation from Amgen Business Development, F-Prime Capital Partners, venBio, Osage University Partners, Longevity Fund companies, and Baxter International
Series B (2018): $110M led by DUMAC, Adage Capital Management, Brace Pharma Capital, OCV Partners, Agent Capital, Amgen Business Development, Ridgeback Capital, Leerink Partners, Cormorant Asset Management, Alexandria Venture Investments, ArrowMark Partners, venBio, Gilead Sciences, F-Prime, Osage University Partners, Longevity Fund companies, Cowen Healthcare Investments, Vivo Capital, Pontifax AgTech, RA Capital Management, and Franklin Templeton Investments
Debt (2019): $40M supported by Undisclosed
Stock Issuance/Offering (2019): $145.4M featuring Undisclosed
Key Investors in Precision BioScience
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, including those developing drugs, medical devices, diagnostics, and research tools.
venBio
venBio is a life sciences investment firm that partners with industry leaders to develop innovative medicines and technologies, focusing on novel therapeutics for unmet medical needs.
Franklin Templeton Investments
Franklin Templeton is a global investment management organization providing specialized investment capabilities across multiple asset classes including equity, fixed income, and alternative investments.
What's next for Precision BioScience?
With the infusion of $145.4M, Precision BioScience is poised to transition into a more mature phase of its corporate lifecycle. The company is expected to prioritize the scaling of its clinical pipeline, moving key therapeutic candidates through rigorous regulatory milestones. Strategic focus will likely remain on optimizing its genome editing efficiency and expanding its collaborative network with global pharmaceutical partners. As the firm continues to refine its platform, the focus will shift toward long-term commercialization strategies, ensuring that its scientific breakthroughs translate into scalable, market-ready solutions that address both human health and agricultural sustainability.
See full Precision BioScience company page
